SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Lowered by Wall Street Zen

SAB Biotherapeutics (NASDAQ:SABS) was downgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Sunday.

A number of other brokerages have also recently commented on SABS. Rodman & Renshaw restated a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a report on Monday, May 11th. Zacks Research upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Jefferies Financial Group started coverage on shares of SAB Biotherapeutics in a research report on Wednesday, May 20th. They set a “buy” rating and a $11.00 price target on the stock. Citigroup started coverage on shares of SAB Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $11.00 price objective for the company. Finally, Barclays initiated coverage on shares of SAB Biotherapeutics in a report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.

SAB Biotherapeutics Stock Up 6.2%

NASDAQ:SABS opened at $3.79 on Friday. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $3.67 and its two-hundred day moving average is $3.83. SAB Biotherapeutics has a 52 week low of $1.85 and a 52 week high of $5.15. The stock has a market capitalization of $289.78 million, a price-to-earnings ratio of -1.80 and a beta of 0.53.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Research analysts anticipate that SAB Biotherapeutics will post -1.19 EPS for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

Institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. purchased a new position in SAB Biotherapeutics in the first quarter valued at $29,000. State of Wyoming acquired a new stake in SAB Biotherapeutics in the fourth quarter valued at $34,000. State Street Corp purchased a new stake in SAB Biotherapeutics during the 4th quarter worth about $49,000. Fifth Lane Capital LP purchased a new stake in SAB Biotherapeutics during the 4th quarter worth about $56,000. Finally, ADAR1 Capital Management LLC purchased a new stake in SAB Biotherapeutics during the 3rd quarter worth about $30,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.